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Department of Laboratory Medicine, The First Afﬁliated Hospital of Chongqing Medical University, Chongqing, ChinaAbstractAlthough heteroresistance is common in a wide range of microorganisms, carbapenem heteroresistance among invasive Escherichia coli
infections has not been reported. The objective of this study was to evaluate the clinical signiﬁcance of carbapenem heteroresistance and
to identify risk factors for its acquisition. A case–control study was conducted at a 3200-bed teaching hospital in Chongqing,
southwestern China. Successive and non-duplicate nosocomial E. coli isolates (n = 332) were obtained from July 2011 to June 2013.
Bloodstream isolates made up 50.6% of the strains collected. The rates of heteroresistance were 25.0% to imipenem, 17.2% to
ertapenem, and 3.9% to meropenem. The population analysis proﬁle revealed the presence of subpopulations with higher carbapenem
resistance, showing MICs ranging from 2.0–128.0 mg/L. Male gender, invasive intervention, antibiotic use and bacterial extended-
spectrum β-lactamase (ESBL) production contributed to invasive infections by carbapenem-heteroresistant E. coli (CHEC). The
production of ESBL was identiﬁed as the common independent risk factor for heteroresistance to both ertapenem and imipenem. Pulsed-
ﬁeld gel electrophoresis revealed clonal diversity among the CHEC isolates. Most importantly, characterization of two successive E. coli
strains isolated from the same patient indicated that carbapenem resistance evolved from heteroresistance. In conclusion, the high
prevalence of heteroresistance to carbapenem among invasive E. coli merits great attention. Routine detection of ESBLs and the prudent
use of imipenem and ertapenem are advocated. The early targeted intervention should be formulated to reduce CHEC infection and
carbapenem resistance of E. coli.
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The ﬁrst three authors contributed equally to this workIntroductionRecent data have revealed a high incidence of community and
nosocomial infections by Gram-negative bacilli [1–4]. Enter-
obacteriaceae, most of which colonize humans, are dominant
causes of these infections worldwide, owing to microbialClinical Microbiology and Infection © 2014 European Society of Cevolution and selection in the presence of broad-spectrum
antimicrobial agents. The accumulation of insusceptibility or
resistance factors (hydrolytic enzyme production, efﬂux pumps,
and porin deﬁcits, or their combinations) has certainly resulted
in the emergence and dissemination of multidrug-resistant
Enterobacteriaceae [5–7]. Extended-spectrum β-lactamase
(ESBL) producers have been frequently identiﬁed in
community-onset urinary tract infections, intra-abdominal in-
fections, and healthcare-related infections, and have led to the
treatment failure of third-generation and fourth-generation
cephalosporins, aminoglycosides, and ﬂuoroquinolones, leav-
ing carbapenems as ‘the last resort’ and ‘the best choice’.
However, the extensive consumption of carbapenems [8] and
the unexpected and worrying prevalence of carbapenemasesClin Microbiol Infect 2015; 21: 469.e1–469.e10
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2014.12.013
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is limited, causing fears about the availability of ideal antibiotics
to overcome carbapenem-resistant Enterobacteriaceae (CRE)
and necessitating a better understanding of the evolution of
CRE.
As anticipated, local and worldwide surveillance of CRE is
ongoing [10]. However, the emergence of phenotypically het-
eroresistant Enterobacteriaceae and the poor performance of
automated susceptibility systems in detecting these microor-
ganisms have potentially resulted in an underestimation of the
extent of carbapenem-resistant epidemiology and evolutionary
processes, resulting in treatment failure. Moreover, whereas
Enterobacter cloacae [11], Acinetobacter baumannii [11–13] and
Klebsiella pneumoniae [14] have been well documented in terms
of heteroresistance traits, Escherichia coli, which is more
frequently identiﬁed in bacteraemia (especially in healthcare
settings), has not been well studied.
Accordingly, the clinical surveillance of carbapenem-
heteroresistant E. coli and predisposing factors for its acquisi-
tion are urgently needed. To the best of our knowledge, this is
the ﬁrst study to report non-homogeneous heteroresistance to
carbapenems among invasive E. coli isolates and their clinical
evolution from carbapenem heteroresistance to resistance.
This is also the ﬁrst study to describe the prevalence of non-
homogeneous carbapenem-heteroresistant E. coli (CHEC) and
risk factors for its acquisition.Materials and methodsStudy design and data collection
This retrospective case–control study of nosocomial E. coli
infections was conducted from July 2011 to June 2013 in the
First Afﬁliated Hospital of Chongqing Medical University, a
3200-bed teaching hospital in Chongqing, southwestern China.
Data were retrieved from the hospital information system and
the laboratory information system. Isolates were collected from
sterile body ﬂuids of patients with culture evidence of noso-
comial infection with E. coli. Antibiotic susceptibility tests were
ﬁrst completed with the Vitek2 compact (bioMerieux, Hazel-
wood, MO, USA), and the MICs were later conﬁrmed with the
broth microdilution method in the presence of carbapenems.
Carbapenem heteroresistance was tested with the disk diffu-
sion method on Mueller–Hinton agar (MHA) (Pangtong Medical
Devices, Chongqing, China) with bacterial suspensions (0.5
McFarland standard) and paper disks containing 10 μg of imi-
penem, ertapenem or meropenem (Thermo Fisher Oxoid,
Basingstoke, UK) and MIC gradient strips (bioMerieux).
Following incubation at 35°C for 24 h, colonies inside the in-
hibition zone were considered to be CHEC, and isolates lackingClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectcolonies inside the inhibition zone were considered to be non-
CHEC. Isolates without an inhibition zone were deﬁned as
carbapenem fully resistant isolates. With this strategy, the E. coli
isolates were divided into three groups. Because carbapenem
fully resistant isolates were rare in this hospital setting, only
CHEC and non-CHEC cases were enrolled, as the case and
control cohorts, respectively. CHEC cases were further fol-
lowed to determine the potential clinical evolution of hetero-
resistance in response to the antibiotic pressure of
carbapenems. Two clonally related E. coli strains, No. 1021 and
No. 88, were further studied, owing to their apparent evolution
from heteroresistance to resistance.
Demographic and epidemiological data were age, gender,
chronic underlying diseases, previous hospital stay, hospital
wards, previous antibiotic agent use and combined adminis-
tration, and ESBL production.
Deﬁnitions
Sterile body ﬂuids were deﬁned as specimens that were
collected from sterile sites with sterile procedures, such as
blood, peritoneal ﬂuid, cerebrospinal ﬂuid, pleural ﬂuid, joint
ﬂuid, and tissue biopsy from internal body sites, among other
sites.
Previous antibiotic agent use was considered to have
occurred if the antibiotics had been used for more than three
consecutive days within 30 days before the isolation of invasive
E. coli.
Heteroresistance to two or more antimicrobial agents was
considered to be co-heteroresistance.
Population analysis proﬁling (PAP) of E. coli isolates
Carbapenem heteroresistance was determined by PAP for
strains that showed different carbapenem MICs and for the
standard carbapenem-susceptible E. coli control isolate ATCC
25922. To achieve this goal, one colony from a culture grown
overnight on Columbia agar (Pangtong Medical Devices) was
inoculated into 5 mL of Luria–Bertani broth (Pangtong Medical
Devices). After 24 h of incubation, 0.1 mL of the starting bac-
terial suspension with a density corresponding to 0.5 McFarland
was serially diluted and spread onto MHA containing two-fold
serial dilutions of imipenem, ertapenem, or meropenem
(Merck & Co., Whitehouse Station, NJ, USA), with concen-
trations ranging from 0.25 to 256 mg/L. One hundred micro-
litres of ten-fold serial dilution(s) of a 0.5 McFarland suspension
was spread on drug-free MHA and incubated for 48 h at 37°C
to determine the CFUs/mL. Colony counts from three replicate
plates were performed for all of the isolates, and mean values
were estimated. The number of resistant cells in 0.1 mL of
starting bacterial suspension was calculated, and the log CFUs/
mL was plotted against the antibiotic concentration. Theious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 469.e1–469.e10
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in the presence of the highest drug concentration was calcu-
lated by dividing the number of colonies that grew on the
antibiotic-containing plate by the colony counts from the same
inoculum that grew on antibiotic-free plates. To evaluate the
stability of the heteroresistance phenotypes for each strain,
three distinct colonies grown in the presence of the highest
drug concentration were subcultured daily in antibiotic-free
medium for >1 week, and the carbapenem MIC was tested
with the broth microdilution method.
Pulsed-ﬁeld gel electrophoresis (PFGE)
Twenty-eight CHEC isolates were randomly selected. Ac-
cording to our previously reported protocol [15], total chro-
mosomal DNA was digested with XbaI, and PFGE ﬁngerprinting
was performed. Chromosomal DNA restriction patterns were
interpreted according to Tenover’s criteria to determine their
genetic relationship.
Statistical analysis
A bivariable analysis was conducted to determine the associa-
tion between potential risk factors and the acquisition of CHEC
infection by comparing the CHEC and non-CHEC groups.
Categorical variables were compared by use of the χ2 test or
Fisher’s exact test. Continuous variables were compared by use
of Student’s t-test or the Wilcoxon rank sum test, depending on
the validity of the normality assumption. Variables with a p-
value of <0.10 in the univariate test were used in a multivariate
one-step logistic remodel. The OR and 95% CI were calculated
to evaluate the strength of any association. A two-tailed p-value
of <0.05 was considered to be statistically signiﬁcant. All of the
statistical calculations were performed with standard programs
in SPSS v.21.0 (SPSS, Chicago, IL, USA).ResultsCarbapenem heteroresistance in clinical invasive E. coli
isolates veriﬁed by PAP
In our laboratory, most of the antibiotic susceptibility tests
were performed with the Vitek2 compact (bioMerieux), ac-
cording to the ‘susceptible’ interpretive criteria for carbapenem
MICs of the CLSI (M100-S24) (ertapenem, 0.5 mg/L; imipe-
nem, 1 mg/L; and meropenem, 1 mg/L). However, owing to
the possibility of heteroresistance, multiresistance or pan-
resistance of pathogens, the procedures used to determine
antibiotic susceptibility were complicated, and all of the
carbapenem-susceptible isolates were conﬁrmed with the pa-
per disk method or with MIC gradient strips. Interestingly,
recurrent growth of colonies within the inhibition zones of theClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infcarbapenem disks (Fig. 1) and MIC gradient strips (Fig. 2) were
suspected, and these subpopulations with different phenotypic
expression showed different resistance levels. For instance, the
PAP results for P8591 and X4412 (randomly selected) revealed
the growth of resistant subpopulations in the presence of
ertapenem at concentrations as high as 4 mg/L and 128 mg/L,
respectively. The proportions of resistant subpopulations that
were able to grow at the highest drug concentrations were
8 × 10−8 for P8591 at 4 mg/L and 1.8 × 10−7 for X4412 at
128 mg/L. The ertapenem MIC values further obtained with the
broth microdilution method were 4 mg/L for P8591 (consid-
ered to be ‘low-level resistance’) and 256 mg/L for X4412
(considered to be ‘high-level resistance’).
The high prevalence of carbapenem heteroresistance
among clinical invasive E. coli isolates
During the investigation period, 332 non-duplicate E. coli iso-
lates were identiﬁed, and 114 isolates were heteroresistant to
carbapenems. The overall incidence of CHEC was 34.3%. Only
two isolates were fully resistant to ertapenem. The greatest
prevalence of heteroresistance was observed for imipenem (83/
332, 25.0%), followed by ertapenem, with a prevalence of 17.2%
(57/332); the incidence of heteroresistance to meropenem was
relatively low in this hospital (13/332, 3.9%). Interestingly, co-
heteroresistance to carbapenems was also observed. Co-
heteroresistance to both imipenem and ertapenem was
observed frequently in 20 cases, whereas co-heteroresistance
to both imipenem and meropenem and co-heteroresistance
to both ertapenem and meropenem were observed in one
and four cases, respectively. Co-heteroresistance to imipenem,
ertapenem and meropenem was observed in seven cases. The
imipenem and meropenem disks revealed the absence of fully
resistant isolates.
The distribution of clinical invasive E. coli isolates and
heteroresistance traits
More than half of the specimens (168/332, 50.6%) were ob-
tained from bloodstream samples, followed by peritoneal ﬂuid
(abdominal ﬂuid and ascites, 90/332, 27.1%) and drainage ma-
terial or tissue biopsies from internal body sites, including
specimens obtained from surgery or aspiration from one of the
following locations: lymph nodes, brain, heart, liver, spleen,
vitreous ﬂuid, kidney, pancreas, ovary, or vascular tissues (60/
332, 18.1%). A majority of the invasive cases were identiﬁed at
the departments of hepatobiliary surgery and gastrointestinal
surgery, and in the intensive-care unit. Furthermore, CHEC
isolates were conﬁrmed most frequently from bloodstream
isolates (48.2%), followed by peritoneal ﬂuid and drainage ma-
terial or tissue biopsies from internal body sites, with a similar
incidence of 23.7%. Hepatobiliary surgery provided a largeectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 469.e1–469.e10
FIG. 1. Characteristics of clinical invasive Escherichia coli with heteroresistance traits on carbapenem disks. (a) Satellite colonies on the meropenem
disk for some clinical isolates with heteroresistance to meropenem. (b) Zone phenomena on the imipenem disk for some clinical isolates with
heteroresistance to imipenem. (c) Zone phenomena and satellite colonies on the ertapenem disk for some clinical strains with heteroresistance to
ertapenem. (d) Zone phenomena and satellite colonies on carbapenem disks for some clinical isolates showing co-heteroresistance to meropenem,
imipenem, and ertapenem.
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intestinal surgery (19.3%) and the intensive-care unit (14.9%).
Risk factors for the acquisition of CHEC
The distribution of 332 invasive E. coli isolates was compared
between CHEC and non-CHEC patients. To identify risk fac-
tors for the acquisition of CHEC, 83 patients with imipenem-
heteroresistant E. coli (IHEC) infections were ﬁrst compared
with 249 patients with non-IHEC infections, given the high
prevalence of IHEC (Table 1). In the univariate analysis, enema,
invasive catheterization and central venous catheterization
were signiﬁcantly more common in patients with IHEC. Inter-
estingly, isolates from drainage materials or tissue biopsies from
internal body sites were signiﬁcantly more likely to acquire the
IHEC phenotype (18.1% vs. 8.4%, p 0.014), and ESBL producers
were more prone to harbour heteroresistance traits (59.0% vs.Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect31.3%, p 0.000). It is of note that there were no signiﬁcant
differences between the IHEC and non-IHEC groups following
prior exposure to carbapenems, penicillins, cephalosporins,
aminoglycosides, or ﬂuoroquinolones, whereas a glycopeptide-
based regimen was adopted signiﬁcantly less often by the IHEC
group (2.4% vs. 8.8%, p 0.05). A multivariate logistic regression
analysis ﬁnally showed that ESBL production was an indepen-
dent risk factor (OR 2.891; 95% CI 1.686–4.959; p 0.000) and
that previous use of glycopeptides (OR 0.194; 95% CI
0.041–0.909; p 0.037) was an unexpected independent pro-
tective factor for the acquisition of IHEC. The Hosmer–
Lemeshow test indicated a good ﬁt for the data (p 0.865). The
c-statistic was 0.711 (Table 2).
Different risk factors were discovered for ertapenem-het-
eroresistant E. coli (EHEC) and for IHEC. A univariate analysis
revealed that male gender, previous antimicrobial use, previousious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 469.e1–469.e10
FIG. 2. Characteristics of clinical carbapenem-heteroresistant Escherichia coli isolates in the carbapenem MIC gradient strips. (a) Zone phenomena and
satellite colonies in the ertapenem MIC gradient strips for some clinical strains with heteroresistance to ertapenem. (b) Zone phenomena and satellite
colonies in the meropenem MIC gradient strips for some clinical isolates with heteroresistance to meropenem. (c) Satellite colonies observed in the
imipenem MIC gradient strips for some clinical isolates with heteroresistance to imipenem.
CMI Sun et al. Impact of carbapenem heteroresistance 469.e5use of aminoglycosides and ESBL production were risk factors
for the acquisition of EHEC. A multivariate analysis ﬁnally
showed that male gender (OR 2.284; 95% CI 1.213–4.301; p
0.011) and ESBL production (OR 2.318; 95% CI 1.260–4.264; p
0.007) were independently associated with EHEC infection. The
Hosmer–Lemeshow test indicated a good ﬁt of the data (p
0.948). The c-statistic was 0.704. In addition, on the basis of the
low prevalence of meropenem-heteroresistant E. coli in this
hospital setting, no signiﬁcant independent risk factors were
identiﬁed for the acquisition of meropenem-heteroresistant
E. coli.
First observation in bacteraemia of the clinical
evolution of carbapenem-resistant E. coli through
heteroresistance as an intermediate stage
Although the ‘inevitable’ evolutionary process from hetero-
resistance to resistance has been well recognized, and experi-
mental trials examining clinical isolates in vitro have veriﬁed thisClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infhypothesis under the selective pressure of antibiotic agents
[16–18], the clinical evolution has remained unknown or
obscure. This is the ﬁrst study to report heteroresistance traits
of invasive E. coli with the goal of describing the clinical outcome
of this subpopulation and of tracking its evolution. Two E. coli
strains (No. 1021 and No. 88) were isolated from the blood-
stream of the same patient during the administration of mer-
openem for recurrent intra-abdominal infections caused by
severe bowel leakage, with an interval of 75 days. The carba-
penem heteroresistance of No. 1021 was characterized by the
growth of satellite colonies within the susceptibility halo in both
the MIC gradient strips and K-B disks, and it was later
conﬁrmed by the PAP results (Fig. 3(a)–(c)). The characteristics
of the PAP curve for the two strains suggested the presence of
several subpopulations with different carbapenem resistance
levels at frequencies between 10−1 and 10−7. Moreover, as
shown in Fig. 3(a), ertapenem-heteroresistant isolates (No.
1021 and No. 88) contained resistant subpopulations that grewectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 469.e1–469.e10
TABLE 1. Clinical and microbial features of 332 patients
infected with invasive Escherichia coli with or without
imipenem heteroresistance
Variables
E. coli isolates
p OR
IHEC
(n [ 83)
Non-IHEC
(n [ 249)
Male, no. (%) 47 (56.6) 111 (44.6) 0.057 1.623
Age (years), median (IQR) 59 (46–70) 62 (45–72) 0.805 —
Previous hospital stay (days),
median (IQR)
5 (2–11) 5 (2–17) 0.329 —
ICU stay, no. (%) 29 (34.9) 73 (29.3) 0.336 1.295
Surgery, no. (%) 47 (56.6) 126 (50.6) 0.341 1.274
Enema, no. (%) 38 (45.8) 81 (32.5) 0.029 1.751
Invasive catheterization, no. (%) 58 (69.9) 141 (56.6) 0.033 1.777
Mechanical ventilation, no. (%) 16 (19.3) 39 (15.7) 0.443 1.286
Urinary catheter, no. (%) 51 (61.4) 132 (53.0) 0.181 1.413
Central venous catheter, no. (%) 23 (27.7) 44 (17.7) 0.048 1.786
Previous cortical hormone use,
no. (%)
12 (14.5) 37 (14.9) 0.929 0.968
Previous antimicrobial use, no. (%) 66 (79.5) 172 (69.1) 0.067 1.738
Combined antimicrobial use,
no. (%)
37 (44.6) 105 (42.2) 0.701 1.103
Carbapenems, no. (%) 11 (13.3) 40 (16.1) 0.538 0.798
Penicillins, no. (%) 16 (19.3) 42 (16.9) 0.617 1.177
Cephalosporins, no. (%) 46 (55.4) 121 (48.6) 0.281 1.315
Aminoglycosides, no. (%) 14 (16.9) 30 (12.0) 0.262 1.481
Fluoroquinolones, no. (%) 10 (12.0) 25 (10.0) 0.606 1.227
Glycopeptides, no. (%) 2 (2.4) 22 (8.8) 0.050 0.255
Nitroimidazoles, no. (%) 40 (48.2) 98 (39.4) 0.157 1.433
ESBL-producing E. coli, no. (%) 49 (59.0) 78 (31.3) 0.000 3.16
ESBL, extended-spectrum β-lactamase; ICU, intensive-care unit; IHEC, imipenem-
heteroresistant E. coli (i.e. E. coli isolates with colonies that grow within the zone of
inhibition around imipenem susceptibility disks); IQR, interquartile range; non-
IHEC, resistance limited to a zone of inhibition around imipenem susceptibility
disks.
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4 mg/L and 128 mg/L, respectively. The proportions of
resistant subpopulations that were able to grow at the highest
ertapenem concentration were 1.33 × 10−7 for No. 1021 at
4 mg/L and 1.75 × 10−7 for No. 88 at 128 mg/L. Most impor-
tantly, the PFGE analysis demonstrated that these two succes-
sive bacteraemia strains originated from the same clone
(Fig. 3(d)), whereas the MICs of ertapenem evolved from 1 mg/TABLE 2. Multivariate logistic regression analysis of clinical
and microbial features of 332 patients infected with invasive
Escherichia coli with or without imipenem heteroresistance
Variable
IHEC
(n [ 83)
Non-IHEC
(n [ 249) p
Adjusted OR
(95% CI)a
Male 47 (56.6) 111 (44.6) 0.391 1.270 (0.736–2.191)
Enema 38 (45.8) 81 (32.5) 0.202 1.526 (0.797–2.922)
Invasive
catheterization
58 (69.9) 141 (56.6) 0.851 0.927 (0.419–2.050)
Central venous
catheterization
23 (27.7) 44 (17.7) 0.087 1.853 (0.914–3.760)
Previous
antimicrobial use
66 (79.5) 172 (69.1) 0.733 1.145 (0.526–2.490)
Glycopeptide use 2 (2.4) 22 (8.8) 0.037 0.194 (0.041–0.909)
ESBL-producing
E. coli
49 (59.0) 78 (31.3) 0 2.891 (1.686–4.959)
Constant — — 0 0.13
Data are no. (%) unless speciﬁed otherwise.
ESBL, extended-spectrum β-lactamase.
aVariables considered for inclusion in the ﬁnal model included glycopeptide use and
ESBL-producing E. coli.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectL (No. 1021) to 256 mg/L (No. 88) in response to the antibiotic
pressure of meropenem.
To test the stability of the heteroresistance to carbapenems,
the resistance behaviour of the subpopulations with higher
levels of resistance was analysed for strains No. 1021 and No.
88. No. 1021 showed colony growth only in the susceptibility
halos of meropenem and ertapenem, whereas No. 88 had
colonies only in the meropenem inhibition zone. Three indi-
vidual colonies within these susceptibility halos were selected
and successively subcultured daily in antibiotic-free medium,
and later assessed with carbapenem disks to select progeny in
the inhibition halos. Finally, two and ten different progeny
strains from No. 1021 were subjected to PAP to evaluate
ertapenem and meropenem, respectively. Nine different prog-
eny strains from No. 88 were subjected to PAP to evaluate
meropenem. The resulting progeny strains were designated
1021 (n) and 88 (n). The PAP curve for the derivatives of No.
1021 (n) and No. 88 (n) showed a shift to the right to slightly
higher carbapenem concentrations, but the shape and class of
the PAP curve were essentially preserved (Fig. 4(a)–(c)). The
PAP for No. 1021 (the second, third, sixth, ninth and tenth
strains) demonstrated the same trend as that observed for No.
1021 (1), with a gradual shift of the curves towards higher
carbapenem concentrations. Again, the overall shape and class
of the curve were maintained; that is, progeny strains did not
show conversion to a homogeneous resistance proﬁle.
Molecular epidemiology of CHEC isolates that cause
invasive infections
To study the clonal relatedness among CHEC isolates, 28
randomly selected CHEC isolates were analysed by PFGE. The
clonal diversities were determined among the CHEC isolates
and interpreted according to Tenover’s criteria, which indi-
cated that the investigated isolates were epidemiologically
unrelated.DiscussionThe steadily increasing emergence of CRE has become a chal-
lenge for patients, clinicians, microbiologists, and pharmacolo-
gists. Limited options for antimicrobial treatment and high
morbidity and mortality have made CRE surveillance a top
priority. Unfortunately, most Enterobacteriaceae colonize
humans. The majority of these microorganisms are not the
actual target pathogens, and may even function as probiotics in
some circumstances, but the inappropriate use and abuse of
broad-spectrum antibiotics to overcome such colonization not
only results in the failure of clinical therapy and prolongation of
hospital stays, but also leads to the emergence of extensivelyious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 469.e1–469.e10
FIG. 3. Population analysis proﬁling (PAP) and pulsed-ﬁeld gel electrophoresis (PFGE) for isolates No. 1021 and No. 88. The x-axis shows the
carbapenem concentration in micrograms per millilitre, which was used to select subpopulations with higher carbapenem resistance levels. The y-axis
shows the frequency of bacterial cells as the logarithm of the CFUs per millilitre. (a–c) PAP for No. 1021, No. 88, and the standard carbapenem-
susceptible Escherichia coli control isolate ATCC 25922, as plotted against the antibiotic concentrations of ertapenem (a), imipenem (b) and mer-
openem (c). PFGE patterns of the two isolates (d).
CMI Sun et al. Impact of carbapenem heteroresistance 469.e7resistant or pan-drug-resistant strains. These phenomena deﬁ-
nitely complicate the surveillance of the antimicrobial suscep-
tibility of Enterobacteriaceae. Although it is advocated to
appropriately discriminate colonization and infection prior toFIG. 4. The stability of heteroresistance of isolates No. 1021 andNo. 88. Popula
heteroresistance to carbapenems. (a) Two derivatives of No. 1021 obtained
ertapenemdisks (the ﬁrst and the second derivatives are illustrated). (b) Ten der
heteroresistant colony on meropenem disks (the third, sixth, ninth and tenth
successive subculture selection of a single heteroresistant colony on meropen
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infinitiating clinical therapy, both the protracted warfare between
the host and colonizing microorganisms and the trans-situation
of colonization and infection often confuse clinical decision-
making. Accordingly, studies that preclude possibletion analysis proﬁling for the progeny strains of No. 1021 andNo. 88with
by successive subculture selection of a single heteroresistant colony on
ivatives ofNo. 1021 obtained by successive subculture selection of a single
derivatives are illustrated). (c) Nine derivatives of No. 88 obtained by
em disks (the third, sixth and ninth derivatives are illustrated).
ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 469.e1–469.e10
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convincing and authentic information. Thus, the present
investigation consisted of clinical isolates from sterile body sites
that lacked colonization by E. coli. This is the ﬁrst study to
describe invasive E. coli with carbapenem-heteroresistant traits
and to illustrate the prevalence and risk factors for its acqui-
sition. These ﬁndings are considered to be helpful to clinicians
in identifying patients at risk of CRE in a timely manner.
Consistent with previous reports [12], a high prevalence of
CHEC was observed in this study. Although most of the
identiﬁed CHEC isolates were from surgical wards, PFGE did
not reveal an outbreak of CHEC during this investigation. This
ﬁnding may suggest a low level of CHEC transmission. Unlike
what is seen for A. baumannii [19], isolates with hetero-
resistance to imipenem were more common than those with
heteroresistance to meropenem and ertapenem. A potential
explanation for this observation is that the antimicrobial se-
lective pressure of imipenem is stronger than those of erta-
penem and meropenem. It was interesting that co-
heteroresistance was observed more frequently for both imi-
penem and ertapenem. Recently, the extensive utilization of
ertapenem in the clinical setting has caused concerns about the
collateral damage associated with the use of carbapenems.
There are lingering concerns regarding the potential for
compromised strain susceptibility and alterations of the hospital
ecology. A recent systematic review has concluded that the
introduction of ertapenem diminished both the consumption of
group 2 carbapenems and resistance to them [20,21]. Thus, we
inferred that it was not the introduction of ertapenem but the
preferential use of imipenem that played an essential role in the
prevalence of carbapenem heteroresistance in the present
study. Furthermore, indiscriminate use of carbapenems and a
disregard of stewardship initiatives have facilitated the evolution
of resistance. The present ﬁndings revealed an interim stage of
heteroresistance to carbapenems, which was veriﬁed by the
presented clinical case. Under the selective pressure of mer-
openem, clinical invasive E. coli isolates with heteroresistance
traits for carbapenems were resistant to carbapenems, sup-
porting concern regarding the aforementioned ‘inevitable’
evolutionary process. Because much less clinical evidence was
available for resistance and co-heteroresistance to meropenem,
further studies are needed to illustrate the relevant mecha-
nisms, under the premise that increased use of imipenem would
decrease the proportion of meropenem use and sustain its
higher intrinsic activity and the susceptibility to it. Note that,
because routine antibiotic susceptibility testing platforms in the
laboratory tend to falsely identify heteroresistant isolates as
‘susceptible’ [11], a high level of attention should be given to
this subpopulation to achieve effective antibiotic therapy.
Collectively, the appropriate use of meropenem and theClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectcautious use of imipenem and ertapenem are advisable for
stewardship of carbapenem therapy in this hospital setting.
Surprisingly, previous exposure to carbapenems, penicillins,
cephalosporins, aminoglycosides or ﬂuoroquinolones was not
associated with the acquisition of CHEC in the present study.
Nevertheless, the tremendous antibiotic pressure has acceler-
ated the evolution of microbial resistance, and prior use of
carbapenems is a plausible risk factor for CRE [22,23]. A 4-year
investigation in Taiwan revealed no signiﬁcant correlation be-
tween carbapenem consumption and resistance among Enter-
obacteriaceae [24]. Several case–control studies have also
indicated that cumulative antibiotic exposure rather than any
one speciﬁc type of exposure determines the odds of gaining
reduced susceptibility elements [25,26]. Our results suggest
that exposure to one speciﬁc class of antimicrobial agent in the
previous 30 days is not a risk factor for CHEC acquisition, and
subsequent studies should focus on the cumulative effect of
antibiotic exposure and the number of antibiotic days. Unex-
pectedly, previous use of glycopeptides was identiﬁed as an
independent protective factor for the acquisition of IHEC. A
potential explanation for this ﬁnding is an increase in the
propagation of Gram-negative bacteria resulting from the ca-
pacity of glycopeptides to overcome Gram-positive bacteria.
The reduction in competitive pressures or environmental
stresses by glycopeptides facilitates the dispersion of fast-
growing E. coli, triggering the intrinsic growth-centric feed-
back loop. Consequently, population-based strategies have
turned to adaptation rather than to the high-expressing and
slow-growing phenotypes (probably heteroresistant or resis-
tant subpopulations) and the hydrolysis of antibiotics for sur-
vival [16,27]. However, the signiﬁcance of this ﬁnding remains
unknown.
Furthermore, ESBL production was a common independent
risk factor for heteroresistance to both ertapenem and imipe-
nem, and was considered to be potentially involved in the co-
heteroresistance to ertapenem and imipenem. ESBL pro-
ducers more commonly harboured co-heteroresistant traits.
This result was consistent with other recent studies focusing on
the determination of carbapenem resistance in Enter-
obacteriaceae [28–30]. Our latest study results revealed a high
prevalence (96.7%) of ESBLs in E. coli isolates that are not
susceptible to carbapenem, especially CTX-M-type ESBL [31].
In addition, mechanistic research has revealed that ESBL pro-
duction, porin deﬁciency and elevated β-lactamase expression
reduce ertapenem susceptibility in E. coli [6,7]. These ﬁndings
suggest that ESBLs participate in the evolution of E. coli from
heteroresistance to carbapenem resistance. Routine detection
of ESBLs is advocated, and elucidation of the underlying
mechanisms will facilitate the development of novel antibiotics
and decelerate or stem the so-called ‘inevitable’ evolution.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 469.e1–469.e10
CMI Sun et al. Impact of carbapenem heteroresistance 469.e9Another interesting ﬁnding of the present study was that
male gender was independently associated with the acquisition
of EHEC. Gender as a risk factor for resistance to some anti-
biotics has been described in other settings [32,33], but the
reason for the association between male gender and resistance
is unclear. Previous studies have attempted to investigate the
interaction between host hormones and antimicrobials in E. coli
populations. A larger study investigating antimicrobial resis-
tance in >100 000 E. coli isolates found that puberty and pre-
menopausal age were associated with an increase in resistance
to some antimicrobials [34]. Unlike in the aforementioned
investigation, the mean age of this nosocomial cohort was >60
years, and it is difﬁcult to speculate on the potential role of
hormones in the acquisition of EHEC. However, one possible
explanation may be that a majority of E. coli strains were iso-
lated from blood and most bacteraemias caused by E. coli
originate from urinary tract infections, and males are more
prone to suffer from this condition than women at this
advanced stage.
This study had some limitations. First, molecular analyses,
especially for the detection of carbapenemases, were not
conducted. Nevertheless, our recent 1-year study showed that
the most common carbapenemase was KPC-2 in nosocomial
scenarios [31]. Additional data have veriﬁed the presence of
IMP-4 and IMP-8 in Chongqing [35,36]. Second, the impact of
cumulative antibiotic exposure was not evaluated. Third, the
clinical outcomes of patients with CHEC and non-CHEC were
not compared.ConclusionsThe results of the present investigation suggest that CHEC
require greater attention from clinicians, researchers, and
pharmacologists, Routine detection of ESBLs and heteroresistant
isolates should be conducted to reduce the risk of empirical
carbapenem therapy failure and the emergence of carbapenem-
resistant E. coli. Meropenem could be used as the carbapenem of
choice to overcome invasive E. coli with ESBL production in this
local setting. If meropenem is used to treat carbapenem-
heteroresistant isolates, then attention to carbapenem MICs,
prolonged infusion at high concentrations and combination with
other antibiotics (with in vitro-conﬁrmed susceptibility) are
advisable. The trend for monitoring of heteroresistance to car-
bapenems and ESBL production among invasive E. coli isolates
increases the possibility of providing early warnings of CRE and
formulating a targeted intervention to reduce the frequency of
CRE infection. Further studies should focus on the mechanisms
of carbapenem heteroresistance or resistance, and the evalua-
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